Mean (SD) | Effect Size | p | ||
---|---|---|---|---|
BILAG Cardiorespiratory Group | ||||
Baseline | C/D/E (n = 195) | 19.2 (11.4) | C/D/E vs B: −0.07 | 0.410 |
B (n = 45) | 20.0 (11.7) | B vs A: 0.39 | ||
A (n = 14) | 15.3 (12.6) | |||
Week 12 | C/D/E (n = 213) | 25.0 (13.1) | C/D/E vs B: 0.02 | NC |
B (n = 16) | 24.8 (12.0) | B vs A: NC | ||
A (n = 1) | 2.0 (NA) | |||
BILAG Hematologic Group | ||||
Baseline | C/D/E (n = 194) | 18.5 (11.2) | C/D/E vs B: −0.26 | NC |
B (n = 56) | 21.4 (12.8) | B vs A: NC | ||
A (n = 4) | 17.5 (9.3) | |||
Week 12 | C/D/E (n = 200) | 24.6 (13.0) | −0.16 | 0.403 |
B (n = 30) | 26.7 (13.4) | |||
BILAG Mucocutaneous Group | ||||
Baseline | C/D/E (n = 71) | 16.9 (9.7) | C/D/E vs B: −0.26 | 0.144 |
B (n = 144) | 19.8 (12.3) | B vs A: −0.06 | ||
A (n = 39) | 20.5 (11.3) | |||
Week 12 | C/D/E (n = 158) | 25.5 (12.9) | C/D/E vs B: 0.14 | 0.452 |
B (n = 57) | 23.7 (13.6) | B vs A: 0.12 | ||
A (n = 15) | 22.1 (12.4) | |||
BILAG Neurological Group | ||||
Baseline | C/D/E (n = 222) | 19.7 (11.7) | C/D/E vs B: 0.52 | NC |
B (n = 26) | 13.8 (9.6) | B vs A: NC | ||
A (n = 6) | 19.5 (9.3) | |||
Week 12 | C/D/E (n = 215) | 25.4 (13.0) | C/D/E vs B: 0.80 | NC |
B (n = 13) | 15.2 (11.5) | B vs A: NC | ||
A (n = 2) | 23.5 (7.8) | |||
BILAG Renal Group | ||||
Baseline | C/D/E (n = 251) | 19.2 (11.6) | NC | NC |
B (n = 3) | 15.3 (10.5) | C/D/E vs B: NC | NC | |
Week 12 | C/D/E (n = 218) | 24.7 (13.1) | B vs A: NC | |
B (n = 9) | 26.6 (10.9) | |||
A (n = 3) | 33.6 (17.0) | |||
BILAG Vasculitis Group | ||||
Baseline | C/D/E (n = 216) | 18.5 (11.0) | C/D/E vs B: −0.55 | NC |
B (n = 30) | 24.8 (14.4) | B vs A: NC | ||
A (n = 8) | 13.6 (6.6) | |||
Week 12 | C/D/E (n = 216) | 24.8 (12.8) | C/D/E vs B: −0.13 | NC |
B (n = 11) | 26.5 (16.4) | B vs A: NC | ||
A (n = 3) | 23.0 (18.2) |
FACIT: Functional Assessment of Chronic Illness Therapy; BILAG: British Isles Lupus Assessment Group; NC: not calculated (when group sample size < 10).